Citigroup

Selected news for the capital firm - Citigroup, collected since 10/2017. Recent stories appear in The Wall Street Journal. This capital firm shares healthcare news with Wells Fargo Securities, LLC, UnitedHealth Group, UnitedHealth, Gilead Sciences, Wolfe Research and hundreds of others.

Please provide a valid email address.

Selected Headines

Date Headline (link) Source Relevant Snippet
1/5/2021 2020 SPAC Boom Lifted Wall Street's Biggest Banks - WSJ The Wall Street Journal ... ÄôNeal to former House of Representatives Speaker Paul Ryan.As celebrities and well-known institutions entered the sector, the biggest banks also increased their activity. Two‚Äî Credit Suisse Group AG CS 5.13% and Citigroup Inc. C 6.94% ‚Äîtogether accounted for nearly 30% of the underwriting, followed by Goldman Sachs Group Inc. GS 5.92%A SPAC is a public firm that uses the money raised from an initial public offering ...
1/4/2021 Illumina (NASDAQ:ILMN) Rating Lowered to Buy at BidaskClub rivertonroll.com ... Piper Sandler upgraded shares of Illumina from a neutral rating to an overweight rating and increased their price target for the company from $340.00 to $415.00 in a research note on Tuesday, December 22nd. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell raised their price objective on shares of Illumina from $330.00 to $335.00 in a report on Wednesday, December 16th. Wolfe Research cut shares of Illumina from ...
1/2/2021 Stryker (NYSE:SYK) Price Target Increased to $252.00 by Analysts at BTIG Research slatersentinel.com ... reports about the company. Robert W. Baird boosted their price target on Stryker from $243.00 to $258.00 and gave the company an “outperform” rating in a report on Thursday, November 12th. Smith Barney Citigroup upped their target price on Stryker from $232.00 to $240.00 in a report on Friday, October 30th. Morgan Stanley upped their target price on Stryker from $225.00 to $272.00 and gave the stock an “overweight ...
1/2/2021 Brokerages Set Surgery Partners, Inc. (NASDAQ:SGRY) Target Price at $26.64 Dakota Financial News ... company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $26.64.SGRY has been the subject of several analyst reports. Smith Barney Citigroup boosted their target price on Surgery Partners from $28.00 to $35.00 and gave the stock report on Thursday, December 10th. Bank of America upped their price objective on Surgery Partners from $21.50 to $25.00 and ...
1/2/2021 Sabra Health Care REIT, Inc. (NASDAQ:SBRA) Receives Consensus Rating of “Hold” from Brokerages theenterpriseleader.com ... SBRA shares. Mizuho upped their target price on shares of Sabra Health Care REIT from $14.00 to $16.00 and gave the stock a “buy” rating in a research note on Friday, October 2nd. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell upped their target price on shares of Sabra Health Care REIT from $14.00 to $17.00 in a research note on Tuesday, December 15th. Smith Barney Citigroup ...
1/2/2021 Arcturus Therapeutics (NASDAQ:ARCT) Stock Rating Lowered by Robert W. Baird slatersentinel.com ... December 1st. Roth Capital downgraded shares of Arcturus Therapeutics from a buy rating to a sell rating and set a $77.00 target price for the company. in a report on Wednesday, December 23rd. Finally, Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell increased their price target on shares of Arcturus Therapeutics from $62.00 to $133.00 in a report on Monday, December 14th. Two analysts have rated the stock ...
1/2/2021 HC Wainwright Downgrades Arcturus Therapeutics (NASDAQ:ARCT) to Neutral baseballnewssource.com ... Barclays downgraded Arcturus Therapeutics from an overweight rating to an equal weight rating and cut their target price for the company from $68.00 to $46.00 in a research report on Tuesday. Finally, Smith Barney Citigroup lifted their price objective on shares of Arcturus Therapeutics from $62.00 to $133.00 in a research note on Monday, December 14th. Two investment analysts have rated the stock with a sell rating, six have assigned ...
1/2/2021 Arcturus Therapeutics (NASDAQ:ARCT) Stock Rating Lowered by Barclays Dakota Financial News ... 68.00.A number of other research firms have also recently commented on ARCT. BidaskClub cut Arcturus Therapeutics from a strong-buy rating to a buy rating in a research report on Monday, December 28th. Citigroup began coverage on shares of Arcturus Therapeutics in a report on Tuesday, October 6th. They set a buy rating and a $65.00 price target for the company. Smith Barney Citigroup upped their price objective on ...
1/2/2021 Endava (NYSE:DAVA) Downgraded by Zacks Investment Research baseballnewssource.com ... healthcare, retail and consumer goods, media and technology and communication industry. Endava Plc is based in London, United Kingdom. “ Get Endava alerts:DAVA has been the topic of a number of other reports. Citigroup upgraded shares of Endava from a neutral rating to a buy rating and boosted their target price for the stock from $57.00 to $67.00 in a report on Wednesday, September 16th. Needham & Company LLC upped ...
1/2/2021 Healthpeak Properties (NYSE:PEAK) PT Raised to $33.00 at Barclays rivertonroll.com ... to $33.00 in a report published on Tuesday morning, Stock Target Advisor reports. The brokerage currently has an overweight rating on the stock.Other equities research analysts also recently issued reports about the stock. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell increased their price target on shares of Healthpeak Properties from $28.00 to $30.00 in a report on Tuesday, December 15th. Wells Fargo & Company downgraded shares of ...
1/2/2021 BidaskClub Lowers Syneos Health (NASDAQ:SYNH) to Buy Daily Political ... on the stock. Credit Suisse Group lifted their price objective on shares of Syneos Health from $72.00 to $75.00 and gave the company an “outperform” rating in a report on Monday, December 7th. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell raised their target price on shares of Syneos Health from $75.00 to $80.00 in a research note on Wednesday, December 9th. Mizuho raised their target price ...
1/2/2021 Syneos Health (NASDAQ:SYNH) Stock Rating Lowered by BidaskClub zolmax.com ... BidAskClub reports.SYNH has been the subject of several other reports. ValuEngine raised shares of Syneos Health from a “sell” rating to a “hold” rating in a report on Saturday, November 21st. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell upped their price objective on shares of Syneos Health from $75.00 to $80.00 in a report on Wednesday, December 9th. The Goldman Sachs Group raised shares ...
1/1/2021 The Goldman Sachs Group Reiterates GBX 6,400 Price Target for AstraZeneca PLC (AZN.L) (LON:AZN) com-unik.info ... Capital reduced their price objective on shares of AstraZeneca PLC (AZN.L) from GBX 9,770 ($127.65) to GBX 9,430 ($123.20) and set a buy rating for the company in a report on Thursday, December 17th. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell reiterated a buy rating on shares of AstraZeneca PLC (AZN.L) in a report on Monday, December 14th. Credit Suisse Group set a GBX 9,500 ($124.12) price ...
1/1/2021 Endava (NYSE:DAVA) Stock Rating Lowered by Zacks Investment Research rivertonroll.com ... healthcare, retail and consumer goods, media and technology and communication industry. Endava Plc is based in London, United Kingdom. “ Get Endava alerts:A number of other brokerages have also recently commented on DAVA. Citigroup upgraded shares of Endava from a “neutral” rating to a “buy” rating and boosted their target price for the company from $57.00 to $67.00 in a report on Wednesday, September 16th. 140166 boosted ...
1/1/2021 Raymond James Downgrades Arcturus Therapeutics (NASDAQ:ARCT) to Market Perform baseballnewssource.com ... rating to a strong sell rating in a research note on Tuesday, November 10th. ValuEngine downgraded Arcturus Therapeutics from a buy rating to a hold rating in a research note on Tuesday, December 1st. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell lifted their price objective on Arcturus Therapeutics from $62.00 to $133.00 in a research note on Monday, December 14th. Smith Barney Citigroup increased their target price ...